Omeros’ newly presented gpr174 immuno-oncology data at esmo immuno-oncology congress show inhibition of both checkpoint and tumor-promoting factors

Seattle--(business wire)--omeros corporation (nasdaq: omer) last week presented new data directed to its novel cancer immunotherapy target gpr174 at the european society for medical oncology (esmo) 2019 immuno-oncology congress in geneva, switzerland. in addition to previously reported findings, which revealed enhanced anti-tumor immune responses in gpr174-deficient mice and synergism between adenosine receptor antagonists and gpr174 antagonists in promoting interleukin-2 (il-2) and interferon-
OMER Ratings Summary
OMER Quant Ranking